Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-268019 versus COMIRNATY in children aged 5 to 11 years for COVID-19 prevention
jRCT2031220493Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing S-268019 with COMIRNATY (2 arms). Primary endpoints: Geometric mean titer of SARS-CoV-2 neutralizing antibody on Day 57, Seroconversion rate of SARS-CoV-2 neutralizing antibody on Day 57 and 2 more. Started Nov 2022; status: completed.
02
Drugs
S-268019-btozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031220493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220493.